RESOLVED: Shareholders of Amgen, Inc. (“Amgen”) request that the Board of Directors commission a racial equity audit to analyze Amgen’s impacts on civil rights, equity, diversity and inclusion, as well as the impacts of those issues on Amgen’s business.

The audit may, at the board’s discretion, be conducted by an independent third party with input from civil rights organizations, employees, communities in which Amgen operates, and other stakeholders.

A report on the audit, prepared at reasonable cost and omitting confidential or proprietary information, should be publicly disclosed on Amgen’s website within a reasonable amount of time.

Supporting Statement: Recent events, including the murder of George Floyd, have galvanized the movement for racial justice and equity. That movement and the disproportionate impacts of the COVID-19 pandemic have focused the attention of media and policymakers on systemic racism, racial violence, and inequities throughout society.

Companies across the spectrum can benefit from assessing the risks of products, practices, services, and overall corporate practices that are or could be perceived to be discriminatory, racist, or that could contribute to increasing inequality.

Following controversies, Facebook and Starbucks conducted civil rights and equity audits that assisted each company to identify, prioritize, and implement improvements. These efforts provide an emerging model for such audits, which have typically been conducted by a third party, in collaboration with experts in civil rights, and with input from an array of stakeholders.

Because such an audit would either improve Amgen’s standing – or further set it apart as a leader that can inspire others – shareholders urge Amgen to commission a racial equity audit of its policies, practices, products, and services so as to evaluate the company’s impact on civil rights, equity, diversity and inclusion, as well as the impacts of those issues on our company’s business.